Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Interest & Investment Income (2023 - 2025)

Prime Medicine filings provide 3 years of Interest & Investment Income readings, the most recent being $1.1 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 29.58% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 17.8% increase, with the full-year FY2025 number at $4.1 million, up 17.8% from a year prior.
  • Interest & Investment Income hit $1.1 million in Q4 2025 for Prime Medicine, down from $1.1 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.5 million in Q4 2024 to a low of $410000.0 in Q3 2023.
  • Median Interest & Investment Income over the past 3 years was $697000.0 (2024), compared with a mean of $837000.0.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 213.24% in 2024 and later dropped 29.58% in 2025.
  • Prime Medicine's Interest & Investment Income stood at $491000.0 in 2023, then skyrocketed by 213.24% to $1.5 million in 2024, then dropped by 29.58% to $1.1 million in 2025.
  • The last three reported values for Interest & Investment Income were $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $743000.0 (Q2 2025) per Business Quant data.